A company named Nafferton, distributor of Boston Scientific, managed to drive all other companies out of the market via legislation:
http://www.elobservador.com.uy/con-monopolio-stents-otros-fa...
A year ago, the Court of Appeals annulled that, and we now can have more that one supplier (not sure if that's in practice now)
http://www.elpais.com.uy/informacion/gobierno-se-encamina-an...
Edit: Court of Appeals, not Supreme Court. Not sure if it reached the Supreme Court.
Perhaps the easiest way we can do something about this is make some noise. But we need indisputable facts in order to do that.
Edit: If you do decide to blow the whistle, please try to stay anonymous as best you can.
Russian company: Angioline (http://www.angioline.ru, the site is Russian-only)
US company: Medtronic (http://www.medtronic.com)
Oligarch: Victor Vekselberg (https://en.wikipedia.org/wiki/Viktor_Vekselberg)
Joint-venture created by Vekselberg and Medtronic for "technology transfer": http://stentex.ru/en/about/company_news/199
Ties in the government: http://www.renova.ru/en/press-center/releases/21/1995/
Single-source decree of the government: https://rg.ru/2015/05/14/stent-site-dok.html (sorry, I can't find English version)
Don't be fooled by the press releases above - no actual transfer or localisation has been done or planned in the nearest future, they are just moving stents from Medtronic to Russia.
As I recall DOJ declined to file charges against Medtronic in a previous 4-5 year investigation of their practices regarding payments to govt doctors in Europe and Malaysia so there is probably a 10-K Form in the 2012-2103 timeframe.
DOJ/SEC have been actively pursuing health services and health technology companies so there is an open ear to complaints.
0: https://www.justice.gov/criminal-fraud/case/related-enforcem...
Exactly
It could be a good case for FCPA investigation, though I doubt that the US will be interested in opening the FCPA case against the American company.
FWIW a lot FCPA cases are against American companies since it's an American rule. The only way a non-American company would end up against FCPA is if they were traded in US financial markets (so Renova Group couldn't be brought up on FCPA charges, but Medtronic definitely can be).
I just don't see what good will it do in Russia. They just reply with "it's all fabricated lies of our enemies in the West!" and it seems to be good enough for majority of population.
shame is an effective tool as a catalyst for change (sometimes)
Corruption is bad, no doubt. But the double standard applied to medical companies makes no sense. If not saving lives is the same as taking ones, then many of the things developed by Silicon Valley are morally abhorrent. How many lives could be saved if the billions of dollars flowing into Facebook, Twitter, Tindr, YouTube, Netflix, etc. were used to buy or develop medicine? I could save the life of a kid in Africa suffering from malaria, but instead I chose to purchase a new Apple Watch. If people actually applied your moral principle in a non-hypocritical way, we'd have almost nothing to talk about on HN.
If you only meant that to apply to the EpiPen, and not to Russians being killed by their own government because of corruption related to cardiac stents, you chose a really weird way to go about it.
https://theintercept.com/2016/08/24/epipen-uproar-highlights...
It gives three examples:
1) Lobbying to not let Medicare negotiate with drug manufacturers. Which is a perfectly reasonable policy to avoid a creating a monosopny buyer of drugs.
2) Lobbying for the Generic Drug User Fee Act. That law imposed fees on the industry to beef up FDA resources for reviewing applications of generics. It also imposed testing requirements on foreign production facilities equal to the testing requirements imposed on domestic facilities. Again, seems reasonable, and the Act was supported by public interest organizations.
3) Lobbying for federal funding to be used to purchase EpiPens for schools. Somewhat shady, but how does that kill anybody?
The problem with #2 is that it creates artificial scarcity. In this case, there is plenty of justification as you don't want shady medicine on the market. The question is whether the FDA is being overcautious with generics and imports. As of now there's certainly plenty of people illegally importing prescription medicine from offshore pharmacies in an unregulated manner, because prescription prices are so inflated compared to most countries.
Lobbying does not produce some of the outright corruption that bribery does, but I've seen more than my fair share of lobbying encouraged laws in the US over the years where a subtext of the law was to eliminate competition. I'm not sure how much of current drug law is pharmaceutical industry influence (my gut feel is some but not all) but some of it definitely, for good reasons or not, blocks up the "invisible hand" of competitive forces.
At least the good thing about a system like the US (vs. the Russian example) is that there's some hope that public outrage over the most egregious examples (your Martin Shkrelis and whatnot) will cause some changes.
I also agree that the case of Mylan is not as dramatic as that of the Russian heart stent company.
http://slatestarcodex.com/2016/08/29/reverse-voxsplaining-dr...
RE the killing vs. not saving, let's maybe put it more precisely - it's decisions that kill people vs. decisions that prevent someone else from saving people. Now in a way, the whole economy indeed runs on the second kind - as long as medical research and medical care aren't money-saturated (i.e. have more of it than know what to do with), all the money that flows somewhere else is preventing lives from being saved. One issue is, we can't just simply redirect all that money to medicine without the world (or at least the country trying) going straight to hell.
As for personal moral responsibility, I think it kind of depends on the "degrees of separation" from the issue. In the Russian stents case, I'd say that what happened is pretty close to mass murder. The separation between patients and the company is just one somewhat fixed legal system, that was about to save lives if it was not for the company. That's like if someone was jumping from a burning building, and last-second you pulled the life net away from where that person was landing. It's not you who killed them, it's the dv/dt...
Most of us, including Netflix, YouTube, et al. are much further separated from life-and-death issues. Like, if I work for a company automating some part of manufacturing in a factory, should I be responsible for a worker who got hit by downsizing? Don't know, I sometimes do feel that way. Should I be responsible for that worker not being able to pay his barberer, who had to start working overtime to compensate, and then didn't have time to go to the gym, and died of a heart condition? There's no way to do that in practice - there's too many variables in between me and that dying person to pin responsibility on one actor, or to even determine the casual chain.
Economy at large is kind of "causality laundering" - too many variables, too much things happening, for a single bad outcome to depend on a single actor if they're not directly connected. But the Russinan thing? Sounds as explicit and direct as one can get without pulling the trigger themselves.
Being dead, he likely wouldn't.
Moral and logic (in the narrowest sense of the word) often don't go hand in hand. That having been said, your point is quite close to my own understanding.
You're misrepresenting the issue by exaggerating in the opposite direction. It isn't "we built twitter instead of saving people". It's that some people have a life threatening problem, a company already has the solution to that problem but they charge a (perhaps unreasonably - depending on who you ask) large sum for it, they actively suppress competitors who provide it for much much cheaper (thus saving lives), and finally they do it for a profit motive (which is perhaps petty - depending on who you ask).
Yes, it's not murder, but on the scale, it's still closer to that part of the spectrum rather than the good side. The reason I say this is that I don't think it's unreasonable to conclude that this company chooses profits over saving lives, for whatever reason. If pharma companies truly valued saving lives over profits, they would reinvest some of those profits into actually saving lives instead of hoarding them. I don't envy those whose job it is to do that calculation.
Your point about anti-competitive conduct is well-taken. But beyond that, it's government's obligation to make sure everyone who needs life-saving treatment has it. But going into the business of saving lives shouldn't entitle you to any less of a profit motive than going into businesses that don't even save lives at all.
Did the American company invent stents and was just protecting their R&D returns from evil Russian copycats? Also the "active suppression" issue is here - apparently the company bribed the government to prevent the competition. The point is more like "it's more immoral to be a life-saving cure provider who decides to make more money from it by shutting down competition that can provide that cure cheaper, than to not be in the life-saving business entirely".
> The money invested in Twitter's IPO alone could've saved more than half a million kids from malaria.
True only if taken out of context of the economy at large. There was no point in time where someone could make a business decision and whole money invested in Twitter's IPO would go directly to cure malaria. That money was not controlled by Twitter, but by many people who invested in it, each having a personal choice of what to do with their wealth.
> it's more immoral to develop a cure and make lots of money from it, than to spend billions on activities that don't even cure anything
OK, when you put it this way, yeah, it's hard to argue against.
What I was going for was more about the after-the-fact of having developed a cure: there's something about the fact that they /have/ the cure and at that point choose not to make it more available that seems reprehensible. This to me seems analogous to the sad fact that people are dying of hunger all the time in the world but a lot of us are isolated from that fact by sheer distance and go about our lives ignoring that with no moral weight on our shoulders (analogy to twitter, not having developed a cure - and not to say that this is a good thing), but if we directly encounter a person dying of hunger one day and we have food (analogy to insert-pharma-here), I'd like to think most of us would feel obligated to help. The immediacy and ability to help seems a factor.
Besides I thought (IANAL) this "maximize shareholder value" meaning short-term-economic-gain meme was massively misinterpreted and needs to die soon?
Otherwise locking someone in a room and not feeding them would not count as murder.
Well, if you read the comment you're replying to you'll see that, in fact, it does.
I disagree vehemently and fervently that the medical industry as whole should be lumped into the latter group: letting people die by passivity. In the poster's story, it's very clear that the US company is they very opposite of passive and worked quite hard to exclude the company with the less expensive product from the market. For sure, this isn't all on the US company and corruption in the state played a big role as well. Still, I don't think it's reasonable to excuse the US company as "just trying to make money".
We want to maximize human quality of life.
People dying of a heart attack does not fit that goal, and a few corrupt politicians and some medical company executives and stockholders making millions while thousands also does not fit. Devoting the whole economy to keeping people alive, but not letting them enjoy that life does not fit either.
A middle path of efficient markets in areas where that works, and of artificially supporting and regulating areas where market forces do not produce the desired outcome due to a lack of profitability or externalities, is not that hard to understand. It's just hard to implement.
The baseline is that -- in the real world -- there are people with skills and equipment and they may or may not put those skills and equipment to use. You can maybe get them to agree to work on producing and developing medicine instead of software. But most of those people and equipment aren't really qualified for that. For the most part, it would just be a huge waste of talent.
However, in theory, this could still lead to some kind of progress in medicine (after all, those people are supposed to be smart), but that depends on whether the key to better medicine lies indeed within the field itself. Also, those gains would still have to outweight whatever benefits occur as a side effect of business as usual, for example when an AI that was developed so teens can better sext each other turns out to be useful in automated diagnostics (or something unexpected like that).
You're absolutely correct that if we chose to apply the standard of "how many lives could this money have saved" to everything we'd never get anything done. But we can be judicious where we choose to wield that standard.
There is at least one line and that is law and it is crossed in most countries at the moment you e.g. bribe officials.
With that out of the way a judge shoud have at keast some leeway if he thinks what they did was unethical to begin with.
Non-emergency stents are a different question. It seems like there is an increasing body of evidence that they do not prolong life, just as you said.
I have no reason to doubt the OP's assertion of corruption in the Russian medicine market, as I have worked with several people who did research in the US and practiced medicine in Russia and have heard similar stories from them.
However, the OP's assertion that more stents = more lives saved is not entirely true as you and the above poster point out. They are clearly well studied and known to save lives, reduce long term morbidity from heart failure, etc.. in the setting of STEMI (ST elevation myocardial infarction, in other words a big acute heart attack).
However, a large number are placed for angina and many studies have shown that they may not make a difference. There are risks with the procedure of placing them, the issues of having to take blood thinning medications afterwards, and so on.
I guess the reason I wanted to comment is to expand this discussion a little because more stents (as the OP wants) in Russia doesn't necessarily mean more lives saved, but it does mean more business for OP. I do not know if there is such a shortage of stents in Russia that emergent catheterization is avoided, if someone knows this to be the case please correct me.
Also, I don't want to come off as implying that the OP is corrupt or only in it to make money. Medicine is complex and (at least in my current opinion) probably benefits from a business side seeking to maximize profits through innovation as long as it is countered with health care workers (and I guess federal oversight) scrutinizing things towards the patient's best health to act as a counterbalance.
And your point that some applications of stents can be useless or even dangerous are also valid, but we should take in consideration the other factor - number of stent operations per 1M of population. Russia is still way back from the value recommended by WHO, which means there are still a lot of people who need stents for live-saving purpose.
Medtronic is the US company (Ireland HQ of course..) partnered with them.
Sources (conveniently removed, Google cache version): http://webcache.googleusercontent.com/search?q=cache:YVnPx9a...
Victor's relationship with PM: http://uk.reuters.com/article/uk-russia-vekselberg-pm-idUKKC...
So am I correct in understanding that the Russian healthcare system lets tens of thousands of people die every year because they can't get stents?
Isn't that true of any nation's healthcare system? They do have finite budgets, and have to make decisions to draw a line somewhere.
This is the point that was blown out of proportion during the Obamacare debates, where the GOP claimed the legislation would involve "death panels". This caricature was hyperbolic enough to backfire, but the fact remains that there's always going to be a decision about where to invest scarce resources.
Not for coronary stents in the U.S. If needed to treat a heart attack, a coronary stent is administered regardless of the patient's ability to pay. Generally speaking, emergency treatment is available to all humans in the U.S. regardless of ability to pay. You might get a bill afterward, but first they will save your life.
As for prophylactic coronary stents, the little bit I've read about them suggests that they don't actually keep people from dying, compared to other cheaper and less invasive treatments.
In America, the coverage provided by Medicaid, Medicare, and private plans under ACA rules, will determine whether to approve or deny a treatment plan based on a number of criteria, which are largely based on a balance between the cost of the treatment versus its likelihood of resulting in additional QALYs (Quality-Adjusted Life Years) for the patient. An expensive treatment that's unlikely to help, or even a less-expensive treatment for somebody who's already 90 years old, is likely to be approved. Thus, there are potential treatments that the government will deny.
You're right that in America, emergency acute care is going to be provided in any case. This was true before ACA, and in this context may be seen as one way that the American system, as defective as it might be, is still better in many ways than is commonly admitted. (Source: my wife's job used to be Medicare reimbursement, and now centers on "DSH" payments to hospitals, which is essentially reimbursing hospitals for bad debts from indigent care and stuff like we're discussing in this sub-thread)
Why can't a patient just buy a stent from your company (vs. asking the govt. to pay for it) and ask their doctor to "install" it? Is that illegal?
(I have no idea how the Russian healthcare system works whatsoever.)
Of course you may pay for the operation by yourself and don't expect any compensation - but this option is not affordable for 90% of the population.
But maybe not, I'm not Russian and don't know what the rules are there.
The "because of greed" way of phrasing these things seems like a weird place to stop to me. If a rock falls on your head and kills you, I think it's fair to say you died "because of a rock". That seems like the key difference between your situation and everyone else's, that explains why you _in particular_ just died. But it would be weird to say that you died "because of gravity" or "because of the frailty of man".
It's as if I was drunk-driving and drove you over. It would not be said that "the car killed" you, but that "a drunk driver" killed you.
they're thought-terminating cliches.
I'm living in Russia and recently have been involved in medical devices market here. The local market for cardiology stents (little springs they insert non-surgically into your heart to remove artery clogging and prevent heart attack or stroke) has been long occupied by the three US companies. The Russian company I invested in, made their own stent design and launched a production factory in Western Siberia. Our prices are three to four times lower that prices for the same class of stents from the US competitors and the quality is the same or higher. We fought out 15% or the market for the last two years.
I have to say, that almost 99% of all stents in Russia are installed at the cost of the state medical insurance - every person in Russia is covered by this insurance, and that insurance is just sponsored by the state or local budget. The budget allocated to this kind of medical support is fixed, so if the yearly budget is 100M rubles (our local currency) and cost of a manipulation and a stent is 100K rubles then you can install stents in 1000 patients in one year. If the price goes down four-fold, then it will be 4000 patients. And this stent manipulation is a life saver in true sense of this word. So, basically with our stents we can save four times more people's lives, which on a scale of Russia would be tens of thousands of people.
Here enters the greed and corruption. One of the US companies approached one of the most powerful Russian oligarchs with good ties in the government. He lobbied a government decree stating that this US company will be single supplier for cardiology stents starting Jan, 2017. So, all hospitals and clinics are obliged to buy stents only from them, at the price they set. Tens of thousands of Russian people will die each year because of the greed and corruption - and we can't do much about it.